Skip to main content

Health, Subjective

3
Pipeline Programs
6
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Hanmi Pharmaceutical
2 programs
2
HGP1810Phase 11 trial
HIP1701Phase 11 trial
Active Trials
NCT04081857Completed48Est. Aug 2019
NCT04087525Completed31Est. Nov 2018
Alteogen
AlteogenKorea - Daejeon
1 program
1
ALT-BB4Phase 11 trial
Active Trials
NCT05232175Completed290Est. Aug 2022
Celltrion
CelltrionKorea - Incheon
3 programs
CT-P13 SC Auto-injectorPHASE_11 trial
CTL0801PHASE_11 trial
Drug: Treatment APHASE_11 trial
Active Trials
NCT03446976Completed218Est. Jul 2018
NCT05002244Completed37Est. Sep 2021
NCT05009368Completed41Est. Oct 2021
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Cultivating Healthy Intentional Mindful EducatorsN/A1 trial
Active Trials
NCT05791825Completed571Est. Oct 2025
Martin Pharmaceuticals
1 program
rapeseed or soy protein or no proteinN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
rapeseed or soy protein or no proteinN/A1 trial
Active Trials
NCT03620812Completed20Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlteogenALT-BB4
CelltrionCTL0801
CelltrionDrug: Treatment A
Hanmi PharmaceuticalHGP1810
Hanmi PharmaceuticalHIP1701
CelltrionCT-P13 SC Auto-injector
Human BioSciencesCultivating Healthy Intentional Mindful Educators
UNION therapeuticsrapeseed or soy protein or no protein

Clinical Trials (8)

Total enrollment: 1,256 patients across 8 trials

NCT05232175AlteogenALT-BB4

Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

Start: Jan 2022Est. completion: Aug 2022290 patients
Phase 1Completed
NCT05002244CelltrionCTL0801

A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers

Start: Jul 2021Est. completion: Sep 202137 patients
Phase 1Completed
NCT05009368CelltrionDrug: Treatment A

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

Start: Jul 2021Est. completion: Oct 202141 patients
Phase 1Completed
NCT04081857Hanmi PharmaceuticalHGP1810

A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

Start: Jun 2019Est. completion: Aug 201948 patients
Phase 1Completed
NCT04087525Hanmi PharmaceuticalHIP1701

A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects

Start: Oct 2018Est. completion: Nov 201831 patients
Phase 1Completed
NCT03446976CelltrionCT-P13 SC Auto-injector

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

Start: Feb 2018Est. completion: Jul 2018218 patients
Phase 1Completed
NCT05791825Human BioSciencesCultivating Healthy Intentional Mindful Educators

Evaluation of the CHIME Intervention for Improving Early Head Start/Head Start Educator Well-being

Start: Mar 2023Est. completion: Oct 2025571 patients
N/ACompleted
NCT03620812UNION therapeuticsrapeseed or soy protein or no protein

Influence of Rapeseed Proteins on the Postprandial Metabolic Response

Start: Aug 2018Est. completion: Dec 201920 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.